Asia Pacific Outbound Medical Tourism Market Size, Share, Growth, Trends and Industry Analysis: By Disease Indication and Country Forecast 2020-2031
Asia Pacific Outbound Medical Tourism Market was valued at US$ 5,200 million in 2024 and is projected to reach US$ 8,700 million by 2031, growing at a 7.7% CAGR during the forecast period (2025 – 2031). The market is undergoing a structural transformation, with increasing disposable incomes, improved health awareness, and changing patient expectations fuelling cross-border health travel. Patients from countries such as China, Australia, South Korea, and Japan are increasingly seeking foreign treatment, yes, not just for cost reasons but also for new treatments, shorter wait times, or access to cutting-edge medical technology that is not available domestically. From voluntary cosmetic surgery to complex oncology treatments, outbound travel is comprehensively testing value, safety, and quality of outcomes. Asia Pacific's middle-class population is more educated and digitally empowered, actively seeking medical destinations and packages. With greater consumer power in healthcare, outbound medical travel is evolving from cost-driver to quality- and experience-driven decision-making.
Medical travel from Asia Pacific is no longer the preserve of the niche; today it is symptomatic of broader socioeconomic and cultural flows. Middle-class expansion, particularly in China and Southeast Asia, has created a new generation of mobile, health-aware consumers who equate wellness with traditional care. These are Singapore and Australia, with their strong health infrastructures that are also fuelling the outflows due to overcharged domestic fees and treatment delay. Further, increased demand for fertility tourism, wellness therapies, and preventive diagnostics is transforming the range of services sought abroad. Destination countries in Europe, North America, and the Middle East are competitively adapting goods to access Asia Pacific patients, sometimes by means of multilingual centres, concierge care, and packaged deals.
Based on the disease indication
Cosmetic procedures have been one of the leading generators of medical tourism for outbound Asia Pacific travel, particularly from working professionals and city millennials. Cosmetic procedures such as facial rejuvenation, liposuction, and rhinoplasty are increasingly sought after in countries such as South Korea, Thailand, and Turkey, which offer cutting-edge technology and seclusion to recuperate. In nations such as China and the Philippines, where standards continue to improve at breakneck speeds as far as appearance is concerned, individuals are going overseas for international services due to high success rates, experienced surgeons, and good post-surgery care. Through increased social media awareness, increased affordability, and the pervasiveness of upgrade procedures, cosmetic medical tourism is becoming an aspirational, lifestyle-driven option rather than a remedial or specialty-specific need.
One of the major drivers of Asia Pacific medical tourism expansion is the gap between rising patient needs and indigenous healthcare deficits. As India and China develop their healthcare infrastructure, higher-end treatments, especially oncology, organ transplant, and reproductive medicine, are unavailable, too expensive, or have unacceptable waiting periods. The new urban middle class are richer and more travel-prone to get faster, newer therapy. Apart from that, greater knowledge of foreign treatment standards, backed by social networks, medical forums, and telemedicine platforms, has enhanced the capability of patients to compare overseas options, quality markers, and treatment choices.
Despite mounting interest in cross-border health care, there still are many areas of friction that are keeping medical tourism in the Asia Pacific in check. Preeminent among them is a deficiency of clearly established regulatory systems and continuity of care uncertainty. Patients can typically face challenges with visa certification, insurance constraints, and medical documentation requirements for foreign travel for care. Foreign legal systems and host country languages could also complicate the care process. Follow-up care after treatment is also a significant issue, especially in the case of surgery and chronic illness patients, who may not have scheduled follow-up care when they return home. While digital health platforms are beginning to bridge these gaps, the current ecosystem remains fragmented, with little extensive integration of sending and receiving healthcare professionals.
Specialist and preventive care offer the greatest potential for Asia Pacific outbound medical tourism. South Korean, Chinese, and Australian affluent patients are seeking more and more destinations offering high-end services such as precision oncology, advanced fertility treatment, robotic surgery, and anti-aging therapy. Medical tourism facilitators and overseas hospitals are catching up and promoting their services through bundled packages, second opinion consultation, and personalized concierge treatment. Preventive diagnosis, executive health screening, and wellness retreats are also on the rise as magnets. With older and health-savvy Asian Pacific populations, outbound demand will be directed at services that promise long-term wellness, not short-term cure, leaving the way open for a more upscale, service-driven segment for destination providers to aim at.
Among the defining trends for the market is the dramatic rise of fertility tourism, particularly by urban couples in countries like China, South Korea, and Singapore. Driven by the rising prevalence of infertility, delayed parenthood, and strict local regulations around procedures such as IVF or surrogacy, couples are flocking in large numbers to offshore clinics for reproductive health. These countries, including the U.S., Greece, and Georgia, are now in vogue because of their permissiveness, success rates, and application of high-tech reproductive technology. Fertility travel is no longer the option of last choice, it is now more a highly charged, carefully planned and researched holiday for couples financed by medical travel facilitators offering legal, logistical, and psychological support.
China is one of the largest players in the market, fueled by the growing upper-middle class, heightened health awareness, and rising demand for premium medical experience. Even assuming that the domestic healthcare sector continues to improve, numerous Chinese patients’ cross borders to avail themselves of such specialist treatments as advanced oncology, IVF, and tailored diagnostics. Belief in Western health care standards, concerns about over-crowding and counterfeit medicines at home, has driven wealthier Chinese families to seek treatment overseas in countries like the U.S., Germany, and Singapore. Health travel is also a strategic add-on to other types of travel, including education or business travel. Sophistication in online China as consumers also enables informed cross-border health-care decisions.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Market Size in 2024 |
US$ 5,200 million |
|
Market Size in 2031 |
US$ 8,700 million |
|
By Disease Indication |
|
|
By Country |
|
According to PBI Analyst the market is undergoing a significant transformation fueled by rising income levels, growing awareness of international healthcare quality, and delays or limitations in domestic health systems. Patients from China, Australia, and South Korea are leading this trend, seeking advanced procedures like fertility treatments, oncology care, and cosmetic surgeries abroad. Affordability is no longer the sole motive, patients now evaluate care quality, travel comfort, and service personalization. Destination countries are adapting by offering multilingual staff, cultural sensitivity, and bundled treatment packages. As wellness merges with medical need, the market is steadily shifting toward experience-driven, specialty-focused, and premium health travel preferences across the region.
Download Free Sample Report
Asia Pacific Outbound Medical Tourism Market was valued at US$ 5,200 million in 2024 and is projected to reach US$ 8,700 million by 2031, growing at a 7.7% CAGR during the forecast period (2025 – 2031).
Key drivers include rising disposable incomes, long domestic wait times, and limited access to specialized treatments in home countries.
A major trend is the surge in fertility tourism among urban couples, driven by restrictive local regulations and access to advanced care abroad.
| 1.Executive Summary |
| 2. Asia Pacific Outbound Medical Tourism Market Introduction |
| 2.1. Asia Pacific Outbound Medical Tourism Market - Taxonomy |
| 2.2. Asia Pacific Outbound Medical Tourism Market - Definitions |
| 2.2.1.Disease Indication |
| 2.2.2.Country |
| 3. Asia Pacific Outbound Medical Tourism Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Asia Pacific Outbound Medical Tourism Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
| 4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Asia Pacific Outbound Medical Tourism Market By Disease Indication, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 5.1. Cardiac |
| 5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Orthopedic |
| 5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Cosmetic |
| 5.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Cancer |
| 5.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Transplant |
| 5.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Others |
| 5.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 6. Asia Pacific Outbound Medical Tourism Market By Country, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 6.1. China |
| 6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. India |
| 6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Australia and New Zealand (ANZ) |
| 6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Japan |
| 6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 6.5. Rest of APAC |
| 6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
| 6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.5.3. Market Opportunity Analysis |
| 7.China Asia Pacific Outbound Medical Tourism Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 7.1. Disease Indication Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 7.1.1.Cardiac |
| 7.1.2.Orthopedic |
| 7.1.3.Cosmetic |
| 7.1.4.Cancer |
| 7.1.5.Transplant |
| 7.1.6.Others |
| 8.India Asia Pacific Outbound Medical Tourism Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 8.1. Disease Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Cardiac |
| 8.1.2.Orthopedic |
| 8.1.3.Cosmetic |
| 8.1.4.Cancer |
| 8.1.5.Transplant |
| 8.1.6.Others |
| 9.Australia and New Zealand (ANZ) Asia Pacific Outbound Medical Tourism Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 9.1. Disease Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Cardiac |
| 9.1.2.Orthopedic |
| 9.1.3.Cosmetic |
| 9.1.4.Cancer |
| 9.1.5.Transplant |
| 9.1.6.Others |
| 10.Japan Asia Pacific Outbound Medical Tourism Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 10.1. Disease Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Cardiac |
| 10.1.2.Orthopedic |
| 10.1.3.Cosmetic |
| 10.1.4.Cancer |
| 10.1.5.Transplant |
| 10.1.6.Others |
| 11.Rest of APAC Asia Pacific Outbound Medical Tourism Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
| 11.1. Disease Indication Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Cardiac |
| 11.1.2.Orthopedic |
| 11.1.3.Cosmetic |
| 11.1.4.Cancer |
| 11.1.5.Transplant |
| 11.1.6.Others |
| 12. Competition Landscape |
| 12.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 12.2.1.Singapore General Hospital |
| 12.2.2.Mount Elizabeth Hospital |
| 12.2.3.Gleneagles Hospital |
| 12.2.4.Apollo Hospitals |
| 12.2.5.Bumrungrad International Hospital |
| 12.2.6.Raffles Medical Group |
| 12.2.7.Fortis Hospitals |
| 12.2.8.Asan Medical Center |
| 12.2.9.Seoul National University Hospital. |
| 13. Research Methodology |
| 14. Appendix and Abbreviations |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
